Atorvastatin-Driven Methuosis in Glioblastoma: A Biomimetic Nanodrug for Targeted Tumor Therapy

  • ACS Nano. 2026 Apr 14;20(14):10889-10904. doi: 10.1021/acsnano.5c15615.
Xinyan Hao  1  2 Yucheng Tang  1  2 Wenjie Xu  1  2 Ming Wang  3 Jiayi Liu  4 Haitao Yang  5 Pengcheng Sun  1  2 Dehua Liao  6 Xiongbin Hu  1  2 Tiantian Tang  1  2 Hai Huang  1  2 Xinying Liu  1  2 Daxiong Xiang  1  2 Junyong Wu  1  2  7
Affiliations
  • 1. Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • 2. Institute of Clinical Pharmacy, Central South University, Changsha 410011, China.
  • 3. Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • 4. Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
  • 5. Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • 6. Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410031, China.
  • 7. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha 410011, China.
Abstract

Glioblastoma (GBM) is a highly malignant brain tumor. The immunosuppressive microenvironment and resistance to chemotherapy-induced Apoptosis pose significant challenges for treatment. In this study, we found that atorvastatin calcium (AC) can effectively induce methuosis in GBM cells, suggesting its potential as a therapeutic candidate for GBM treatment. To address the challenge of crossing the blood-brain barrier (BBB) and enhance drug delivery efficiency, we synthesized AC nanoparticles stabilized through dopamine polymerization, achieving high drug-loading efficiency. Moreover, the nanoparticles were coated with PD-1-engineered BV2 cell membranes and further modified with Angiopep-2 peptides to facilitate BBB crossing and effective accumulation at the tumor site. In vitro experiments confirmed the cytotoxicity and induction of methuosis in GBM cells by AP@CM-Ang, accompanied by the release of immune-stimulatory factors. In vivo experiments demonstrated that the nanodrug significantly enhanced tumor targeting, effectively inhibited tumor growth, and increased immune cell activation, validating its potential as a promising and safe strategy for GBM treatment.

Keywords
BBB penetration; atorvastatin; glioblastoma; methuosis; nanodrug.
Products